Coherus BioSciences is engaged in developing and commercializing biosimilar drugs of the highest quality and value. The Company’s product candidates include CHS-1701, drug pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.

TypePublic
HQRedwood City, US
Founded2010
Size (employees)127 (est)-3%
Websitecoherus.com
Coherus BioSciences was founded in 2010 and is headquartered in Redwood City, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Coherus BioSciences Office Locations

Coherus BioSciences has an office in Redwood City
Redwood City, US (HQ)
600 333 Twin Dolphin Dr
Show all (1)
Report incorrect company information

Coherus BioSciences Financials and Metrics

Coherus BioSciences Revenue

Coherus BioSciences's revenue was reported to be $1.56 m in FY, 2017
USD

Net income (Q2, 2018)

(88.0m)

EBIT (Q2, 2018)

(86.9m)

Market capitalization (15-Oct-2018)

885.1m

Closing stock price (15-Oct-2018)

13.1

Cash (30-Jun-2018)

130.0m
Coherus BioSciences's current market capitalization is $885.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

31.1m30.0m190.1m1.6m

Revenue growth, %

(3%)533%

General and administrative expense

17.6m36.0m51.6m71.3m

R&D expense

78.2m213.1m254.4m162.4m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

12.4m14.1m

General and administrative expense

4.0m6.1m8.8m10.2m11.4m11.3m13.6m18.8m23.5m16.6m35.0m

R&D expense

18.5m36.5m56.9m68.2m65.3m65.5m64.6m53.8m34.5m25.5m52.0m

Operating expense total

22.5m42.6m65.8m78.4m76.7m76.8m78.2m72.6m58.0m42.0m86.9m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

150.4m158.2m124.9m126.9m

Inventories

1.9m

Current Assets

179.1m197.4m161.5m145.5m

PP&E

4.5m10.5m10.8m12.8m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

100.9m115.1m206.1m153.7m179.6m220.9m159.7m124.9m73.4m82.0m130.0m

Current Assets

118.9m143.9m239.6m189.3m211.6m236.8m177.3m208.3m153.3m112.2m172.8m

PP&E

3.7m5.1m6.3m8.7m10.3m9.9m10.7m14.9m14.5m11.9m11.2m

Goodwill

943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(87.2m)(223.9m)(127.8m)(238.3m)

Depreciation and Amortization

674.0k3.0m3.4m

Accounts Payable

3.6m(5.0m)(3.8m)

Cash From Operating Activities

(23.9m)(252.5m)(200.3m)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(7.9m)(40.8m)(99.9m)(171.4m)(65.5m)(135.7m)(51.8m)(74.8m)(130.2m)(44.3m)(88.0m)

Depreciation and Amortization

632.0k1.3m717.0k1.4m2.2m865.0k1.7m922.0k1.8m

Accounts Payable

4.4m10.9m7.1m19.1m(6.8m)(7.4m)(1.6m)(7.3m)(3.8m)(1.1m)(2.3m)

Cash From Operating Activities

(53.9m)(113.6m)(76.3m)(103.7m)(165.7m)(73.3m)(128.9m)(33.6m)(69.1m)
USDY, 2018

Financial Leverage

3 x
Show all financial metrics
Report incorrect company information

Coherus BioSciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Coherus BioSciences News and Updates

Coherus BioSciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)

REDWOOD CITY, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar. UDENYCA™ is one of the first pegfilgrastim bi…

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective August 14, 2018, the company’s board of directors granted 3 new employees options to purchase an aggregate of 35,500 shares of the company’s common stock with a per shar…

Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results

REDWOOD CITY, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended June 30, 2018.  

Coherus BioSciences Receives Positive CHMP Opinion for UDENYCA™ (Pegfilgrastim Biosimilar Candidate)

REDWOOD CITY, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of UDENYCA™ (formerly CHS…
Report incorrect company information

Coherus BioSciences Company Life and Culture

Report incorrect company information